<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">SPARFLOXACIN</span><br/>(spar-flox'a-sin)<br/><span class="topboxtradename">Zagam<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">quinolone</span><br/><b>Prototype: </b>Ciprofloxacin<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>200 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic quinolone that is a broad-spectrum bactericidal agent. Inhibits DNA-gyrase, an enzyme necessary for bacterial DNA
         replication and some aspects of transcription, repair, recombination, and transposition.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effective against many gram-positive and gram-negative organisms. Indicated by negative cultures and resolution of S&amp;S of
         infection.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of community-acquired pneumonia, acute exacerbations of chronic bronchitis caused by susceptible bacteria.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>History of hypersensitivity or photosensitivity reactions; patients with known QT<sub>c</sub> prolongation, antiarrhythmic agents that prolong the QT<sub>c</sub> interval (e.g., Class 1A and Class III); exposure to sun while taking sparfloxacin; pregnancy (category C), lactation; hypokalemia,
         significant bradycardia, CHF, myocardial ischemia, and atrial fibrillation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>History of seizures; kidney dysfunction with Cl<sub>cr</sub>
</p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Community-Acquired Pneumonia, Bronchitis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 400 mg day 1, then 200 mg q.d. day 210<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Do not give drug within 4 h of drugs containing aluminum, magnesium, iron, zinc, calcium, or sucralfate.</li>
<li>Store at 20°25° C (68°77° F) in a tightly closed container.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, dizziness, insomnia, somnolence. <span class="typehead">CV:</span> Prolonged QT<sub>c</sub> interval on ECG. <span class="typehead">GI:</span> Pseudomembranous colitis, diarrhea, nausea, dyspepsia, abdominal pain, taste perversion, vomiting, flatulence, dry mouth. <span class="typehead">Skin:</span>
<span class="speceff-common">Phototoxicity</span> (burning, redness, swelling, blisters, rash, itching, dermatitis), pruritus, rash. <span class="typehead">Urogenital:</span> Vaginal moniliasis. <span class="typehead">Other:</span> Cartilage erosion. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>May cause false positive on <span class="alt">opiate screening tests.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">magnesium-</span> or <span class="classification">aluminum-containing antacids</span> decrease absorption; torsades de pointes arrhythmias in patients on <b>disopyramide, amiodarone, quinidine, procainamide, sotalol, bepridil.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract. 92% bioavailability. <span class="typehead">Peak:</span> 36 h. <span class="typehead">Distribution:</span> 45% protein bound. Penetrates lower respiratory tract tissues. Crosses placenta, distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in the liver. Does not utilize Cyt P450 enzymes. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 20 h (1630 h). 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Obtain C&amp;S prior to beginning therapy and periodically during therapy.</li>
<li>Do not give sparfloxacin to persons with proarrhythmic conditions such as hypokalemia, CHF, atrial fibrillation, etc.</li>
<li>Discontinue therapy and notify physician immediately if any of the following occur: Skin rash or other signs of a hypersensitivity
            reaction (see Appendix F); skin eruption following sun exposure; symptoms of colitis such as persistent diarrhea; joint pain,
            inflammation, or other signs of rupture of a tendon; CNS symptoms such as seizures, restlessness, anxiety, confusion, hallucinations,
            depression, suicidal ideation.
         </li>
<li>Monitor those at risk for seizures carefully.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn important indications for discontinuing drug and immediately notifying physician.</li>
<li>Drink fluids liberally while taking sparfloxacin.</li>
<li>Allow a minimum of 4 h between drug and any of the following: Aluminum or magnesium antacids, iron and calcium supplements,
            multivitamins with zinc, or sucralfate.
         </li>
<li>Avoid all exposure to direct or indirect sunlight or artificial UV light during treatment and for 5 d after therapy. If brief
            sunlight exposure is necessary, cover as much skin surface as possible with clothing. Discontinue drug at first sign of phototoxicity
            (e.g., burning skin, redness, swelling, itching) and notify physician.
         </li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>